Just saw X4 Pharma got a positive opinion from the European regulator for mavorixafor to treat WHIM syndrome - that's a pretty significant move for such a rare immunodeficiency disorder. The Phase 3 data apparently looked solid enough to convince the committee, and they're expecting the final green light sometime this quarter.

What's interesting is the commercial angle here. They already locked in a deal with Norgine back in January to handle the European rollout, which could bring in over $200M in milestone payments plus royalties on sales. For a rare disease treatment, that's not bad positioning.

Stock was down about 5% when the news hit Thursday, which is kind of odd given it's regulatory progress, but markets can be weird sometimes. Guess some investors were already pricing this in or there's profit-taking happening. Either way, this WHIM syndrome approval is a real validation that their drug candidate works - that's the core win here regardless of short-term stock moves.